This was an exceptionally busy day, what with our exclusive news about Vioxx clinical trials (
please see this) and still more controversy over antidepressants (
please take our poll). Now, though, we must adjourn for a dinner engagement. We look forward to engaging you again tomorrow. Meanwhile, please enjoy these....
Biogen Idec Forecasts Profit Surge On Tysabri Demand (Bloomberg News)
Par Pharmaceutical Reports Long-Delayed Financial Results (Yahoo/Reuters)
IMS Health Exec Predicts Rosy Future For Generics (Yahoo/AP)
Corporate Venture Capital Investing Grows Significantly (Pacific Business News)
1 Comment
Interesting news... Carmelo Lisciotto